

Research & Reviews: Journal of Biology

An Alternative Treatment Modality of Diseases using Photodynamic Therapy with a Wide Range Biological Targeting Possibility

Mehmet VAROL ^{1,2,*}

¹Department of Biology, Faculty of Science, Yunusemre Campus, Anadolu University, Eskisehir TR26470, Turkey

²Department of Molecular Biology and Genetics, Kotekli Campus, Mugla Sitki Kocman University, Mugla TR 48000, Turkey

Editorial

Received date: 16/11/2015
Accepted date: 18/11/2015
Published date: 25/11/2015

*For Correspondence

Mehmet VAROL, Department of Molecular Biology and Genetics, Faculty of Science, Kotekli Campus, Mugla Sitki Kocman University, Mugla TR48000, Tel: 0090-252-211-31-32 / 4839; Fax: +90-252-211-92-80 Turkey.

E-mail: mehmetvarol@mu.edu.tr

INTRODUCTION

With approvals for clinical use by health agencies in most industrial countries such as the United States, the Netherlands, Canada, Japan, Australia, Russia ^[1-3], Photodynamic therapy [PDT] is a very promising and minimally invasive treatment modality for various types of malignant diseases, including but not limited to cancers of lung, breast, bladder, pancreas, liver, ovary, prostate, skin, head and neck, digestive tract and brain, and for wide ranges of non-malignant diseases, such as hypertrophic scarring, ulcers, rheumatoid arthritis, intimal hyperplasia, periodontitis, atherosclerotic plaques, macular degeneration, psoriasis, actinic keratosis, bacterial and fungal infections ^[4].

Photodynamic therapy is based on photosensitizers, light with the corresponding wavelength of the photosensitizers, and tissue oxygen to destroy the target cells and tissues ^[5-10]. The electronic transitions occur from a singlet ground state to a singlet excited state first, and then a triplet excited state by intersystem crossing within the photo-induced molecules which are the main agents of photodynamic therapy ^[7,11-12]. After that, the photosensitizers eliminate the absorbed energy by transfer to tissue oxygen forming singlet oxygen or by transfer to biological substrates, forming semi-oxidized or semi-reduced radicals, which are associated with further electron transfer reactions ^[13-16].

The photosensitized radical chain reactions can lead to the formation of oxidized biological molecules such as lipids, proteins, carbohydrates, nucleic acids and other biologically-relevant molecules including vitamins, natural antioxidants etc. ^[17]. For example, lipophilic photosensitizers can intercalate into acetyl chain department of the phospholipid bilayer and photodynamic therapy-triggered oxidative modification of lipid constituents such as peroxidation of unsaturated phospholipids or production of truncated oxidized lipids [aldehydes and carboxylic acids] can bring membrane leakage and/or lysis, resulting in unregulated necrosis-like cell death ^[18-26]. Moreover, the photosensitized radical-induced oxidative lesions such as 8-hydroxy-2'-deoxyguanosine [8-OHdG] and 8-oxo-7,8-dihydro-2'-deoxyguanosine [8-oxodG] can be occurred, respectively in nuclear and mitochondrial DNA ^[27]. Oxidative attacks on sugar moiety of nucleic acids can be also accomplished by singlet oxygen and reactive oxygen species ^[28-31, 9]. Photo-oxidation of proteins can lead to structural and conformational changes of the peptide skeleton, loss of enzyme activity, differentiation in ligand affinities, mechanical properties and aggregation states, oxidation of other proteins and biological molecules, and deterioration or depletion of intracellular and/or extracellular signaling pathways ^[32-37, 59].

On the other hand, it is also possible to see the photo-oxidations at organelle level such as mitochondria, endoplasmic reticulum, golgi apparatus and lysosomes. For example, photodynamic therapy-triggered lysosomal rupture are associated with release high concentrations of lysosomal enzymes [such as the discharge of cathepsins] into cytoplasm and increase of cytosolic acidification, resulting in lysophagy, apoptosis or non-programmed cell death ^[38, 39]. The proteolytic cathepsins can fracture

the pro-apoptotic member of the Bcl-protein family, BH3 interacting-domain death agonist [BID], to form truncated-BID [t-BID], which are eventuated in apoptosis^[40-42, 26]. Similarly, photo-oxidized the sarcoplasmic reticulum provides a burst of calcium that has been shown to play a substantial role in inducing programmed necrosis and necroptosis signaling pathway^[43-45]. It is also widely known that targeting the endoplasmic reticulum and golgi apparatus could significantly compromise the synthesis and processing of proteins^[46-47, 3]. Mitochondria is the most studied organelle in photodynamic application due to its key role in apoptotic pathway. However, ATP levels depletion, drastic mitochondrial membrane permeability and disruption of mitochondria can be achieved by high PDT-dose treatment, resulting oncosis and non-programmed cell death^[48-50]. Extracellular release of ATP has been assigned as a very potent find-me signal for dendritic cells, monocytes and macrophages. For instance, ATP binding to P2X7 purinergic receptors on dendritic cells can stimulate dendritic cell maturation, and then induction of an anti-tumor adaptive immune response^[51-53, 26]. Furthermore, it is worth mentioning about PDT-mediated immunological responses, occurred by damage-associated molecular patterns [DAMPs], which arise from stressed and dying cells, and operate as danger signals for the host immune system. The best characterized PDT-associated DAMPs are heat shock proteins [HSPs] serve as chaperon proteins that play key roles in the actions including transport and correct folding of new synthesized proteins, prevention of apoptosis and stress conditions, promotion of proteasomal degradation^[54-59]. The exist of HSPs into the extracellular environment stimulates various immune cells and anti-tumor immune response due to the binding properties of HSPs to numerous receptors, related to immune system such as Toll-like receptors [TLR 2 and TLR 4] and cluster of differentiation 91 [CD 91]^[60-63, 26].

Biological outcomes of the PDT-triggered radical-mediated photo-oxidations can cause cell senescence, and autophagic, apoptotic or necrotic cell death by dependent on fluence [J/cm^2] and fluence rates [mW/cm^2] of light, and photosensitizer concentration. Mfouo-Tynga and Abrahamse^[64] reviewed PDT-mediated cell death pathways. However, tumor cells can renovate the outcomes of photodynamic therapy by activating one or more survival- and stress-response pathways, including a direct early stress response that induces proliferation of tumor cells, a hypoxia stress repercussions that rehabilitates energy homeostasis and encourages angiogenesis, a pro-inflammatory signaling response that manages angiogenesis and invasion, an antioxidant response that promotes de nova synthesis of antioxidants, an endoplasmic reticulum response that rehabilitates homeostasis of endoplasmic reticulum^[65]. For many years, apoptosis was regarded as the most wanted result in the PDT-triggered cell death due to the minimal side effects although tumor cells can be resistant to apoptosis, and necrosis was considered as an undesired pathway for PDT-mediated cell death due to the possible initiation of inflammatory responses in the surrounding tissue^[66]. Therefore, PDT-mediated autophagy can be regarded as an alternative to provide more efficient treatments to cells deficient apoptosis^[16]. Additionally, the features of photosensitizers and photo-induced reactive species such as their aggregation and diffusion in nanoenvironment, the specific targets of photosensitizer, singlet oxygen generation quantum yield capacity, fluorescence lifetime, encapsulation, lipophilic and hydrophilic features, and other photo-physical and photo-chemical properties should be considered for an efficient photodynamic therapy^[67-77, 26].

Consequently, photodynamic therapy seems to be the most promising strategy with minimal damage in surrounding tissue, combination possibility with other treatment strategy, perfectible features of different photosensitizers and possible treatment applications for a wide range of diseases. To provide an efficient photodynamic therapy, the researches focused on clinical, *in vivo* and *in vitro*, therefore, should be expanded.

ACKNOWLEDGEMENT

For the financial support of our current photodynamic research project [Project no: 1309F320], we are grateful the Commission of Scientific Research Projects of Anadolu University, Turkey. We are also grateful to all authors who have studied on photodynamic therapy for their precious contribution.

REFERENCES

1. Master A, Livingston M and Gupta AS. Photodynamic nanomedicine in the treatment of solid tumors perspectives and challenges. *J Control Release*. 2013;168:88-102.
2. Ormond AB and Freeman HS. Dye sensitizers for photodynamic therapy. *Mater*. 2013;6: 817-840.
3. Jiang Z et al. Pharmaceutical development composition and quantitative analysis of phthalocyanine as the photosensitizer for cancer photodynamic therapy. *J Pharm Biomed Anal*. 2014;87:98-104.
4. Bechet D et al. Photodynamic therapy of malignant brain tumours a complementary approach to conventional therapies. *Cancer Treat Rev*. 2014;40:229-241.
5. Dougherty TJ. Photodynamic therapy (PDT) of malignant tumors. *Crit Rev Oncol Hematol*. 1984;2:83-116.
6. Gomer C. Photodynamic therapy in the treatment of malignancies. *Semin Hematol*. 1989;26:27-34.
7. Henderson BW and Dougherty TJ. How does photodynamic therapy work?. *Photochem Photobiol*. 1992;55:145-157.
8. Dougherty TJ et al. Photodynamic therapy. *J Natl Cancer Inst*. 1998;90:889-905.
9. Oleinick NL and Evans HH. The photobiology of photodynamic therapy cellular targets and mechanisms. *Radiat Res*. 1998;150:146-156.

10. Castano AP, Mroz P and Hamblin MR. Photodynamic therapy and anti-tumour immunity. *Nat Rev Cancer*. 2006;6:535-545.
11. Marian CM. Spin-orbit coupling and intersystem crossing in molecules. *Wiley Interdisciplinary Reviews.Comput Mol Sci*. 2012;2:187-203.
12. Nguyen KH et al. UV-protectant metabolites from lichens and their symbiotic partners. *Nat Prod Rep*. 2013;30:1490-1508.
13. Foote CS. Mechanisms of photosensitized oxidation. *Sci*. 1968;162:963-970.
14. Frankel E. Chemistry of free radical and singlet oxidation of lipids. *Prog Lipid Res*. 1984; 23:197-221.
15. Braslavsky S, Houk K and Verhoeven J. Glossary of terms used in photochemistry. *Pure Appl Chem*. 1996;79:293-465.
16. Bacellar IO et al. Photodynamic efficiency from molecular photochemistry to cell death. *International journal of molecular sciences*. 2015;16:20523-20559.
17. Halliwell B and Gutteridge J. *Free radicals in biology and medicine* 4th edn. oxford university press. 2007;
18. Girotti AW. Photodynamic lipid peroxidation in biological systems. *Photochem Photobiol*. 1990;51:497-509.
19. Riske KA et al. Giant vesicles under oxidative stress induced by a membrane-anchored photosensitizer. *Biophys J*. 2009;97:1362-1370.
20. Tyrode E et al. Molecular structure upon compression and stability toward oxidation of langmuir films of unsaturated fatty acids a vibrational sum frequency spectroscopy study. *Langmuir*. 2010;26:14024-14031.
21. Broekgaarden M et al. Development and in vitro proof-of-concept of interstitially targeted zinc-phthalocyanine liposomes for photodynamic therapy. *Curr Med Chem*. 2014;21: 377-391.
22. Sankhagowit S et al. The dynamics of giant unilamellar vesicle oxidation probed by morphological transitions. *Biochim Biophys Acta*. 2014;1838:2615-2624.
23. Weber G et al. Lipid oxidation induces structural changes in biomimetic membranes. *Soft Matter*. 2014;10:4241-4247.
24. Ytzhak S and Ehrenberg B. The effect of photodynamic action on leakage of ions through liposomal membranes that contain oxidatively modified lipids. *Photochem Photobiol*. 2014;90:796-800.
25. Runas KA and Malmstadt N. Low levels of lipid oxidation radically increase the passive permeability of lipid bilayers. *Soft Matter*. 2015;11:499-505.
26. Weijer R et al. Enhancing photodynamic therapy of refractory solid cancers combining second-generation photosensitizers with multi-targeted liposomal delivery. *J Photochem Photobiol*. 2015;C 23:103-131.
27. Valavanidis A, Vlachogianni T and Fiotakis C. 8-hydroxy-2'-deoxyguanosine (8-ohdg) a critical biomarker of oxidative stress and carcinogenesis. *J Environ Sci Health C*. (2009); 27:120-139.
28. Sies H and Menck CF. Singlet oxygen induced DNA damage. *Mutat Res*. (1992);275:367-375.
29. Ravanat JL et al. Singlet oxygen induces oxidation of cellular DNA. *J Biol Chem*. (2000) 275:40601-40604.
30. Castano AP, Demidova TN and Hamblin MR. Mechanisms in photodynamic therapy part two—cellular signaling cell metabolism and modes of cell death. *Photodiagnosis and Photodyn Ther*. 2005;2:1-23.
31. Defedericis HC et al. Singlet oxygen-induced DNA damage. *Radiat Res*. 2006;165:445-451.
32. Goosey JD, Zigler JS and Kinoshita JH. Cross-linking of lens crystallins in a photodynamic system a process mediated by singlet oxygen. *Sci*. 1980;208:1278-1280.
33. Escobar J, Rubio M and Lissi E. SOD and catalase inactivation by singlet oxygen and peroxy radicals. *Free Radic Biol Med*. 1996;20:285-290.
34. Michaeli A and Feitelson J. Reactivity of singlet oxygen toward proteins the effect of structure in basic pancreatic trypsin inhibitor and in ribonuclease a. *Photochem Photobiol*. 1997;65:309-315.
35. Silva E et al. Lysozyme photo-oxidation by singlet oxygen properties of the partially inactivated enzyme. *J Photochem Photobiol B*. 2000;55:196-200.
36. Hampton MB, Morgan PE and Davies MJ. Inactivation of cellular caspases by peptide-derived tryptophan and tyrosine peroxides. *FEBS Lett*. 2002;527:289-292.
37. Davies MJ. Singlet oxygen-mediated damage to proteins and its consequences. *Biochem Biophys Res Commun*. 2003;305:761-770.
38. Guicciardi ME, Leist M and Gores GJ. Lysosomes in cell death. *Oncogene*. 2004;23: 2881-2890.
39. Linder S and Shoshan MC. Lysosomes and endoplasmic reticulum targets for improved selective anticancer therapy. *Drug Resist Updat*. 2005;8:199-204.
40. Wilson PD, Firestone RA and Lenard J. The role of lysosomal enzymes in killing of mammalian cells by the lysosomotropic detergent N-dodecylimidazole. *J Cell Biol*. 1987; 104:1223-1229.

41. Berg K et al. Light induced relocalization of sulfonated meso-tetraphenylporphines in nhik 3025 cells and effects of dose fractionation. *Photochem Photobiol.* 1991;53:203-210.
42. Moan J et al. Sulfonated aluminium phthalocyanines as sensitizers for photochemotherapy effects of small light doses on localization dye fluorescence and photosensitivity in V79 cells. *Int J Cancer.* 1994;58:865-870.
43. Trump BF and Berezsky IK. The role of altered $[Ca^{2+}]_i$ regulation in apoptosis, oncosis, and necrosis. *Biochim Biophys Acta.* 1996;1313:173-178.
44. Rizzuto R and Pozzan T. Microdomains of intracellular Ca^{2+} molecular determinants and functional consequences. *Physiol Rev.* 2006;86:369-408.
45. Zong WX and Thompson CB. Necrotic death as a cell fate. *Genes Dev.* 2006;20:1-15.
46. Terasaki M et al. Localization of endoplasmic reticulum in living and glutaraldehyde-fixed cells with fluorescent dyes. *Cell.* 1984;38:101-108.
47. Barr FA and Short B. Golgins in the structure and dynamics of the golgi apparatus. *Curr Opin Cell Biol.* 2003;15:405-413.
48. Kessel D and Arroyo AS. Apoptotic and autophagic responses to Bcl-2 inhibition and photodamage. *Photochem Photobiol Sci.* 2007;6:1290-1295.
49. Andrzejak M, Price M and Kessel DH. Apoptotic and autophagic responses to photodynamic therapy in 1c1c7 murine hepatoma cells. *Autophagy.* 2011;7:979-984.
50. Du L et al. Autophagy inhibition sensitizes bladder cancer cells to the photodynamic effects of the novel photosensitizer chlorophyllin e4. *J Photochem Photobiol B.* 2014; 133:1-10.
51. Elliott MR et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. *Nat.* 2009;461:282-286.
52. Ghiringhelli F et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1 β -dependent adaptive immunity against tumors. *Nat Med.* 2009;15:1170-1178.
53. Zitvogel I et al. Inflammasomes in carcinogenesis and anticancer immune responses. *Nat Immunol.* 2012;13:343-351.
54. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. *Nat Rev Immunol.* 2002;2:185-194.
55. Korbelik M, Sun J and Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins relevance for tumor response. *Cancer Res.* 2005; 65:1018-1026.
56. Zhou F, Xing D and Chen WR. Regulation of HSP70 on activating macrophages using PDT-induced apoptotic cells. *Int J Cancer.* 2009;125:1380-1389.
57. Etminan N et al. Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids *in vitro*. *Br J Cancer.* 2011;105:961-969.
58. Mitra S et al. Tumor response to mthpc-mediated photodynamic therapy exhibits strong correlation with extracellular release of HSP70. *Lasers Surg Med.* 2011;43:632-643.
59. Panzarini E, Inguscio V and Dini L. Immunogenic cell death can it be exploited in photodynamic therapy for cancer?. *Biomed Res Int.* 2012;2013:1-18.
60. Basu S et al. CD91 is a common receptor for heat shock proteins GP96, HSP90, HSP70, and calreticulin. *Immun.* 2001;14:303-313.
61. Thériault JR, Adachi H and Calderwood SK. Role of scavenger receptors in the binding and internalization of heat shock protein 70. *J Immunol.* 2006;177:8604-8611.
62. Stott B and Korbelik M. Activation of complement c3, c5, and c9 genes in tumors treated by photodynamic therapy. *Cancer Immunol Immunother.* 2007;56:649-658.
63. Korbelik M. Complement upregulation in photodynamic therapy-treated tumors role of toll-like receptor pathway and NF κ B. *Cancer Lett.* 2009;281:232-238.
64. Mfouo-tynga I and Abrahamse H. Cell death pathways and phthalocyanine as an efficient agent for photodynamic cancer therapy. *Int J Mol Sci.* 2015;16:10228-10241.
65. Broekgaarden M et al. Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies. *Cancer Metastasis Rev*, in press. 2015;
66. Mohammad RM et al. Broad targeting of resistance to apoptosis in cancer. *Semin Cancer Biol* in press. 2015;
67. Zhou C, Milanese C and Jori G. An ultrastructural comparative evaluation of tumors photosensitized by porphyrins administered in aqueous solution bound to liposomes or to lipoproteins. *Photochem Photobiol.* 1988;48:487-492.
68. Jori G and Reddi E. The role of lipoproteins in the delivery of tumour-targeting photosensitizers. *Int J Biochem.* 1993;25:1369-1375.

69. Sharman WM, van Lier JE and Allen CM. Targeted photodynamic therapy via receptor mediated delivery systems. *Adv Drug Deliv Rev.* 2004;56:53-76.
70. Vakrat-Haglili Y et al. The microenvironment effect on the generation of reactive oxygen species by Pd-bacteriopheophorbide. *J Am Chem Soc.* 2005;127:6487-6497.
71. Pavani C et al. Effect of zinc insertion and hydrophobicity on the membrane interactions and pdt activity of porphyrin photosensitizers. *Photochem Photobiol Sci.* 2009;8:233-240.
72. Silva EF et al. Mechanisms of singlet-oxygen and superoxide-ion generation by porphyrins and bacteriochlorins and their implications in photodynamic therapy. *Chemistry.* 2010; 16:9273-9286.
73. Ding H et al. Photoactivation switch from type ii to type i reactions by electron-rich micelles for improved photodynamic therapy of cancer cells under hypoxia. *J Control Release.* 2011;156:276-280.
74. Oliveira CS et al. Major determinants of photoinduced cell death subcellular localization versus photosensitization efficiency. *Free Radic Biol Med.* 2011;51:824-833
75. Pavani C, Iamamoto Y and Baptista MS. Mechanism and efficiency of cell death of type ii photosensitizers effect of zinc chelation. *Photochem Photobiol.* 2012;88:774-781.
76. Yeh SCA et al. Monitoring photosensitizer uptake using two photon fluorescence lifetime imaging microscopy. *Theranostics.* 2012;2:817-826.
77. Bacellar IO et al. Membrane damage efficiency of phenothiazinium photosensitizers. *Photochem Photobiol.* 2014;90:801-813.